Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
Conditions
- Multiple Myeloma, Newly Diagnosed
Interventions
- DRUG: Elranatamab
- DRUG: Lenalidomide (Revlimid®)
- DRUG: Daratumumab SC (Darzalex)
- PROCEDURE: Autologous Stem Cell Transplantation
- DRUG: Bortezomib (Velcade®)
- DRUG: Dexamethasone
Sponsor
Intergroupe Francophone du Myelome
Collaborators